Market Cap 695.12M
Revenue (ttm) 84.28M
Net Income (ttm) -171.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -203.25%
Debt to Equity Ratio 2.79
Volume 2,933,400
Avg Vol 1,847,670
Day's Range N/A - N/A
Shares Out 99.30M
Stochastic %K 1%
Beta 0.95
Analysts Strong Sell
Price Target $28.67

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 858 771 9307
Address:
11682 El Camino Real, Suite 300, San Diego, United States
ae1213
ae1213 Jul. 21 at 2:23 PM
$SPRY I love to see anxious $AQST enthusiasts posing in the morning. Aww, silly sally has come up with only 6 “bearish signs”, why not 10? I guess he has a very demanding “high power job” and no time to post.
0 · Reply
BigGainTom
BigGainTom Jul. 21 at 2:06 PM
$SPRY Bearish signs: 1. Did not get CVS approval and no timeline in sight for it. 2. Sales peak in the summer and fade beyond that. Sales for this Q have been terrible. 3. Stock is overvalued at 700M market cap for single product company with soon-to-be zero moat. 4. CEO and his girl, the CMO, were fired. 5. Competitors including Anaphylm work faster and are easier to carry, and are coming soon. 6. Removal from Russ 2k.
2 · Reply
SonOfPaul19
SonOfPaul19 Jul. 21 at 1:22 PM
$SPRY don’t listen to these fear mongers. This is buy zone. Forced selling and panic from algos (cvs deferral, ceo/cmo exit, removal from Russell 2000 defensive) just crushed the stock. The fundamentals have not changed. Hopefully the forced selling is done today and I think it is. High volume on huge down day yesterday. Fundamentals are stronger than ever. IQVIA scripts are looking great on BBG. Big growth year on year. Huge doctor prescriber base and growing. Still have $150MIL in untapped credit from RA. Casale hire huge. Will eventually unlock CVS (hopefully inclusion announcement October/november). Remember, it was deferred due to bureaucratic issues including FTC challenges to payers and new legislation to PBMs as a whole. This is his speciality. Commercialization. CSU readout later this year could largely increase the multiples. This is buy zone. Don’t listen to those AQST idiots. $30 Jan 2028.
0 · Reply
BigGainTom
BigGainTom Jul. 20 at 8:03 PM
$GRRR $ASTS $RCAT $SPRY My polls don't lie! Scams getting crushed. Good luck to shorts. Nice gains !
0 · Reply
Master_P_
Master_P_ Jul. 20 at 5:06 PM
$SPRY Notorious loud mouth, Stone52, sure has been quiet. Wonder why!
0 · Reply
Lilwopjob
Lilwopjob Jul. 20 at 4:34 PM
$SPRY just puking all over itself - ugly to watch. once they break through the PBM wall it will absolutely take off I would think but management has been absolutely incompetent since approval...obviously the board agrees. $AQST better be taking not and coming up with a plan to get those PBM's some margins or they will suffer the same fate.
1 · Reply
prototyper
prototyper Jul. 20 at 3:46 PM
$SPRY $4 coming boys.
1 · Reply
ae1213
ae1213 Jul. 20 at 2:53 PM
$SPRY anything is possible, but not before $AQST hits mid 2s after a banner q2. It must be a new channel over there. Keep it up silly sally!
0 · Reply
StockBraker
StockBraker Jul. 20 at 2:24 PM
$SPRY https://www.theglobeandmail.com/investing/markets/stocks/SPRY-Q/pressreleases/3351374/ars-pharmaceuticals-announces-key-executive-leadership-departures/
2 · Reply
BigGainTom
BigGainTom Jul. 20 at 2:16 PM
$SPRY new 365 day low set. I believe this will go to $4 per share
1 · Reply
Latest News on SPRY
ARS Pharmaceuticals announces CEO succession

2026-07-07T20:50:12.000Z - 13 days ago

ARS Pharmaceuticals announces CEO succession

SNY


ARS Pharmaceuticals Announces CEO Succession

Jul 7, 2026, 4:30 PM EDT - 13 days ago

ARS Pharmaceuticals Announces CEO Succession


ARS Pharmaceuticals Provides Commercial and Financial Updates

Jun 24, 2026, 4:05 PM EDT - 26 days ago

ARS Pharmaceuticals Provides Commercial and Financial Updates


ARS Pharmaceuticals Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 2 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2026


ARS Pharmaceuticals Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 2 months ago

ARS Pharmaceuticals Earnings release: Q1 2026


ARS Pharmaceuticals Quarterly report: Q1 2026

May 15, 2026, 8:30 AM EDT - 2 months ago

ARS Pharmaceuticals Quarterly report: Q1 2026


ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)

2026-05-15T10:07:53.000Z - 2 months ago

ARS Pharmaceuticals reports Q1 EPS (61c), consensus (54c)


ARS Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

ARS Pharmaceuticals Proxy statement: Proxy filing


ARS Pharmaceuticals Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

ARS Pharmaceuticals Proxy statement: Proxy filing


ARS Pharmaceuticals initiated with an Outperform at Northland

2026-04-09T11:14:32.000Z - 3 months ago

ARS Pharmaceuticals initiated with an Outperform at Northland


ARS Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 4 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2025


ARS Pharmaceuticals Annual report: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 4 months ago

ARS Pharmaceuticals Annual report: Q4 2025


ARS Pharmaceuticals Earnings release: Q4 2025

Mar 9, 2026, 8:30 AM EDT - 4 months ago

ARS Pharmaceuticals Earnings release: Q4 2025


ARS Pharmaceuticals Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 4 months ago

ARS Pharmaceuticals Slides: Corporate presentation


ARS Pharmaceuticals reports Q4 EPS (42c), consensus (44c)

2026-03-09T10:05:06.000Z - 4 months ago

ARS Pharmaceuticals reports Q4 EPS (42c), consensus (44c)


ARS Pharmaceuticals announces NMPA approval for neffy 2 mg

2025-12-29T13:10:25.000Z - 7 months ago

ARS Pharmaceuticals announces NMPA approval for neffy 2 mg


ARS Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2025


ARS Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ARS Pharmaceuticals Quarterly report: Q3 2025


ARS Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ARS Pharmaceuticals Earnings release: Q3 2025


ARS Pharmaceuticals Slides: Q3 2025

Nov 10, 2025, 8:30 AM EST - 9 months ago

ARS Pharmaceuticals Slides: Q3 2025


ARS Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q2 2025


ARS Pharmaceuticals Quarterly report: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Quarterly report: Q2 2025


ARS Pharmaceuticals Earnings release: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q2 2025


ARS Pharmaceuticals Slides: Corporate Presentation

Jun 2, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Slides: Corporate Presentation


ARS Pharmaceuticals Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q1 2025


ARS Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Quarterly report: Q1 2025


ARS Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q1 2025


ARS Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Proxy statement: Proxy Filing


ARS Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

ARS Pharmaceuticals Proxy statement: Proxy Filing


ARS Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q4 2024


ARS Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Annual report: Q4 2024


ARS Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

ARS Pharmaceuticals Earnings release: Q4 2024


ARS Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 10:30 AM EST - 1 year ago

ARS Pharmaceuticals Slides: FY 2025


ARS Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Earnings Call Transcript: Q3 2024


ARS Pharmaceuticals Quarterly report: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Quarterly report: Q3 2024


ARS Pharmaceuticals Earnings release: Q3 2024

Nov 13, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Earnings release: Q3 2024


ae1213
ae1213 Jul. 21 at 2:23 PM
$SPRY I love to see anxious $AQST enthusiasts posing in the morning. Aww, silly sally has come up with only 6 “bearish signs”, why not 10? I guess he has a very demanding “high power job” and no time to post.
0 · Reply
BigGainTom
BigGainTom Jul. 21 at 2:06 PM
$SPRY Bearish signs: 1. Did not get CVS approval and no timeline in sight for it. 2. Sales peak in the summer and fade beyond that. Sales for this Q have been terrible. 3. Stock is overvalued at 700M market cap for single product company with soon-to-be zero moat. 4. CEO and his girl, the CMO, were fired. 5. Competitors including Anaphylm work faster and are easier to carry, and are coming soon. 6. Removal from Russ 2k.
2 · Reply
SonOfPaul19
SonOfPaul19 Jul. 21 at 1:22 PM
$SPRY don’t listen to these fear mongers. This is buy zone. Forced selling and panic from algos (cvs deferral, ceo/cmo exit, removal from Russell 2000 defensive) just crushed the stock. The fundamentals have not changed. Hopefully the forced selling is done today and I think it is. High volume on huge down day yesterday. Fundamentals are stronger than ever. IQVIA scripts are looking great on BBG. Big growth year on year. Huge doctor prescriber base and growing. Still have $150MIL in untapped credit from RA. Casale hire huge. Will eventually unlock CVS (hopefully inclusion announcement October/november). Remember, it was deferred due to bureaucratic issues including FTC challenges to payers and new legislation to PBMs as a whole. This is his speciality. Commercialization. CSU readout later this year could largely increase the multiples. This is buy zone. Don’t listen to those AQST idiots. $30 Jan 2028.
0 · Reply
BigGainTom
BigGainTom Jul. 20 at 8:03 PM
$GRRR $ASTS $RCAT $SPRY My polls don't lie! Scams getting crushed. Good luck to shorts. Nice gains !
0 · Reply
Master_P_
Master_P_ Jul. 20 at 5:06 PM
$SPRY Notorious loud mouth, Stone52, sure has been quiet. Wonder why!
0 · Reply
Lilwopjob
Lilwopjob Jul. 20 at 4:34 PM
$SPRY just puking all over itself - ugly to watch. once they break through the PBM wall it will absolutely take off I would think but management has been absolutely incompetent since approval...obviously the board agrees. $AQST better be taking not and coming up with a plan to get those PBM's some margins or they will suffer the same fate.
1 · Reply
prototyper
prototyper Jul. 20 at 3:46 PM
$SPRY $4 coming boys.
1 · Reply
ae1213
ae1213 Jul. 20 at 2:53 PM
$SPRY anything is possible, but not before $AQST hits mid 2s after a banner q2. It must be a new channel over there. Keep it up silly sally!
0 · Reply
StockBraker
StockBraker Jul. 20 at 2:24 PM
$SPRY https://www.theglobeandmail.com/investing/markets/stocks/SPRY-Q/pressreleases/3351374/ars-pharmaceuticals-announces-key-executive-leadership-departures/
2 · Reply
BigGainTom
BigGainTom Jul. 20 at 2:16 PM
$SPRY new 365 day low set. I believe this will go to $4 per share
1 · Reply
BigGainTom
BigGainTom Jul. 20 at 2:14 PM
$SPRY hits 365 day low
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Jul. 18 at 10:47 AM
$SPRY ARS Pharmaceuticals Inc. (SPRY) is betting that its needle-free neffy epinephrine nasal spray can transform emergency allergy treatment. Could growing adoption make this stock under $10 a major biotech winner? https://globalmarketbulletin.com/could-ars-pharmaceuticals-spry-disrupt-the-emergency-allergy-treatment-market/
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin Jul. 18 at 8:26 AM
$LXEO $OMER $SBET $SGMT $SPRY Looking for stocks under $10 that could triple? These top 5 stocks have clinical trials, commercial launches, crypto holdings, and major Wall Street support. https://globalmarketbulletin.com/5-stocks-under-10-analysts-believe-could-soar-200/
0 · Reply
OnlyUp01
OnlyUp01 Jul. 17 at 8:14 PM
$SPRY Not too late to hop on the AQST train before it leaves the station. Good luck Neffy competing with the far superior Anaphylm. Have a great weekend.
1 · Reply
Sdwg
Sdwg Jul. 17 at 7:38 PM
$SPRY shorts hitting this hard today, must be the poll...🫤
1 · Reply
CakeorDeath2
CakeorDeath2 Jul. 16 at 10:40 PM
$SPRY anyone catch the Neffy shoutout on Jeopardy the other day?
0 · Reply
BigGainTom
BigGainTom Jul. 16 at 8:40 PM
$SPRY $RCAT $GRRR $ASTS Ended the vote at 69 votes... Looks like GRRR dominated the votes with SPRY and RCAT coming in tied for second. ASTS was fourth but that was before the offering -- possible the vote would have been different today. Stay tuned for the next poll! Good luck to investors!
1 · Reply
BigGainTom
BigGainTom Jul. 15 at 4:49 PM
$GRRR $ASTS $RCAT $SPRY Which highly shorted company is most likely to go to zero?
2 · Reply
Stone52
Stone52 Jul. 10 at 11:30 PM
$SPRY $AQST June 30 short interest updated: SPRY short interest -1.35 million shares. AQST short interest +1.2 million shares.
0 · Reply
BigGainTom
BigGainTom Jul. 10 at 8:52 PM
$SPRY $ASTS $GRRR Why invest in this garbage? These are falling knives.
0 · Reply
Lilwopjob
Lilwopjob Jul. 10 at 6:39 PM
1 · Reply
Lilwopjob
Lilwopjob Jul. 10 at 6:33 PM
1 · Reply